DK2838517T3 - Oralt tilgængelig farmaceutisk formulering, som er egnet til forbedret behandling af bevægelseslidelser - Google Patents

Oralt tilgængelig farmaceutisk formulering, som er egnet til forbedret behandling af bevægelseslidelser Download PDF

Info

Publication number
DK2838517T3
DK2838517T3 DK13725557.6T DK13725557T DK2838517T3 DK 2838517 T3 DK2838517 T3 DK 2838517T3 DK 13725557 T DK13725557 T DK 13725557T DK 2838517 T3 DK2838517 T3 DK 2838517T3
Authority
DK
Denmark
Prior art keywords
agonist
zolmitriptan
pharmaceutical formulation
buspirone
present disclosure
Prior art date
Application number
DK13725557.6T
Other languages
English (en)
Inventor
Mikael S Thomsen
Jens D Mikkelsen
Peter Gudmund Nielsen
Mads Kreilgaard
John Bondo Hansen
Original Assignee
Contera Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2012/050190 external-priority patent/WO2012163365A1/en
Application filed by Contera Pharma Aps filed Critical Contera Pharma Aps
Application granted granted Critical
Publication of DK2838517T3 publication Critical patent/DK2838517T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (15)

1. Oral farmaceutisk formulering omfattende a. en matrixbestanddel, som omfatter en aktiv farmaceutisk bestanddel, som er en agonist af to eller flere af 5-HT1B-, 5-HT1D- og 5-HT1 F-receptorerne, som er en triptan, idet nævnte matrixbestanddel sørger for forlænget frigivelse af den aktive farmaceutiske bestanddel, og b. en bestanddel, som omfatter en aktiv farmaceutisk bestanddel, som er en agonist af 5-HT1A-receptoren, hvilken bestanddel sørger for øjeblikkelig frigivelse af den aktive farmaceutiske bestanddel.
2. Farmaceutisk formulering ifølge krav 1, hvor triptanen er valgt fra gruppen bestående af zolmitriptan, rizatriptan, sumatriptan, naratriptan, almotriptan, frovatriptan, avitrip-tan, imotriptan og eletriptan og farmaceutisk acceptable derivater deraf.
3. Farmaceutisk formulering ifølge krav 1, hvor agonisten af 5-HT1A-receptoren er valgt fra gruppen bestående af buspiron, tandospiron, gepiron, alnespiron, binospiron, ipsapiron, perospiron, befiradol, repinotan, piclozotan, osemozotan, flesinoxan, fliban-serin og sarizotan og farmaceutisk acceptable derivater deraf.
4. Farmaceutisk formulering ifølge krav 1, hvor triptanen er zolmitriptan, og agonisten af 5-HT1 A-receptoren er buspiron.
5. Farmaceutisk formulering ifølge et hvilket som helst af de foregående krav, hvor formuleringen a. er en fast doseringsform, såsom en tablet, b. omfatter matrixbestanddel a. og bestanddel b. i separate rum eller lag, c. omfatter en indre kernematrix, som sørger for forlænget frigivelse af triptanen, og et ydre overtræk, som sørger for øjeblikkelig frigivelse af agonisten af 5-HT1 A-receptoren, d. er en tolagstablet, som omfatter ét lag, der sørger for forlænget frigivelse af triptanen, og et andet lag, der sørger for øjeblikkelig frigivelse af agonisten af 5-HT1A-receptoren, hvor hvert lag er til stede i samme tablet, eller e. hvor hver af bestanddelene a. og b. tilvejebringes sammen i en kapsel, hvor kapslen omfatter bestanddelene a. og b. som separate granulater eller pellets.
6. Farmaceutisk formulering ifølge et hvilket som helst af de foregående krav, hvor ma-trixbestanddelen a. omfatter én eller flere excipienser, hvor excipienserne er valgt fra gruppen bestående af a. frigivelseskontrollerende excipienser, b. hydroxypropylmethylcellulose (HPMC), c. mikrokrystallinsk cellulose (MCC), d. en HPMC-excipiens, som er til stede i en mængde på 20-50%, såsom 20-25%, fx 25-30%, såsom 30-35%, fx 35-40%, såsom 40-45%, fx 45-50%, og e. en MCC-excipiens, som er til stede i en mængde på 50 til 80%, såsom 60-70%.
7. Farmaceutisk formulering ifølge et hvilket som helst af de foregående krav, hvor ma-trixbestanddelen a. a. yderligere omfatter talkum, hvor nævnte talkum er til stede i en mængde på 1-10%, såsom ca. 5%, b. komprimeres til en hårdhed på 50-70N, c. sørger for mindst 80% frigivelse af triptanen efter 12 timer, d. består af én eller flere HPMC'er, én eller flere MCC'er, talkum og en triptan, e. omfatter triptanen i en mængde på fra 0,1 til 10 mg, såsom fra 0,5 til 5 mg, fx omkring 1 mg, og/eller f. omfatter eller består af 10-50%, såsom 20-40%, HPMC; 40-80%, såsom 55-75% MCC; 1-10%, såsom 2-8% talkum; og 0,1-5%, såsom 0,5-2% afen trip-tan.
8. Farmaceutisk formulering ifølge et hvilket som helst af de foregående krav, hvor bestanddel b. omfatter a. en excipiens, b. en filmdannende excipiens, c. en excipiens, som er en hydroxypropylmethylcellulose (HPMC), d. eller består af mindst én HPMC og en agonist af 5-HT1 A-receptoren, e. en agonist af 5-HT1 A-receptoren i en mængde på fra 1 til 20 mg, såsom fra 5 til 15 mg, fx ca. 10 mg, og/eller f. eller består af 25-40% HPMC og 60-75% af en agonist af 5-HT1 A-receptoren.
9. Farmaceutisk formulering ifølge et hvilket som helst af de foregående krav, hvor den formulering, der består af bestanddelene a. og b., omfatter eller i det væsentlige består af a. 20-40% HPMC, b. 50-70% MCC, c. 1-10% talkum d. 0,1-10% af en triptan, som fortrinsvis er valgt fra gruppen bestående af zolmitriptan, rizatriptan, sumatriptan, naratriptan, almotriptan, frovatriptan og eletriptan, e. 1-20% af en agonist af 5-HT1 A-receptoren, som fortrinsvis er valgt fra gruppen bestående af buspiron, tandospiron, gepiron, alnespiron, binospiron, ipsapi-ron, perospiron, befiradol, repinotan piclozotan, osemozotan, flesinoxan, fliban-serin og sarizotan, f. 0,1-10% HPMC, hvor bestanddelene a., b., c. og d. er omfattet i matrixbestanddel a., og bestanddelene e. og f. er omfattet i bestanddel b.
10. Farmaceutisk formulering ifølge et hvilket som helst af de foregående krav, hvor formuleringen omfatter én eller flere yderligere aktive bestanddele.
11. Farmaceutisk formulering ifølge krav 10, hvor den yderligere aktive bestanddel er valgt fra gruppen bestående af dopamin; dopamin-prodrugs; L-DOPA, levodopa; car-boxylaseinhibitorer såsom carbidopa eller benserazid; dopaminreceptoragonister såsom bromcriptin, pergolid, pramipexol, ropinirol, piribedil, cabergolin, apomorphin, lisurid; NMDA-antagonister såsom fx amatidin; catechol-O-methyltransferaser; COMT-inhibitorer såsom tolcapon og entacapon; MAO-B-inhibitorer såsom selegilin og rasagi-lin; serotoninreceptormodulatorer; kappaopioidreceptoragonister såsom TRK-820; GABA-modulatorer; modulatorer af neuronale kaliumkanaler såsom flupirtin og reti-gabin; og glutamatreceptormodulatorer.
12. Farmaceutisk formulering ifølge et hvilket som helst af de foregående krav, hvor formuleringen er til anvendelse i behandlingen afen bevægelseslidelse.
13. Farmaceutisk formulering til anvendelse ifølge krav 12, hvor bevægelseslidelsen er valgt fra gruppen bestående af Parkinsons sygdom, bevægelseslidelser forbundet med Parkinsons sygdom såsom bradykinesi, akinesi og dyskinesi, L-DOPA-induceret dyski-nesi, tardiv dyskinesi, ataksi, akatisi, dystoni, essentiel tremor, Huntingtons sygdom, myoklonus, Rett-syndrom, Tourettes syndrom, Wilsons sygdom, dyskinesier, chorea, Machado-Joseph-sygdom, uro i benene, spasmodisk torticollis, geniospasme eller bevægelsesforstyrrelser forbundet dermed, bevægelsesforstyrrelser forbundet med anvendelse af lægemidler såsom neuroleptiske lægemidler, antipsykotiske midler, anti-depressiva og antiemetika, idiopatisk sygdom, genetiske dysfunktioner, infektioner eller andre tilstande, som fører til dysfunktion af de basale ganglier og/eller fører til ændrede synaptiske dopaminniveauer, og afvænning fra lægemidler.
14. Farmaceutisk formulering ifølge et hvilket som helst af kravene 1 -11 eller farmaceutisk formulering til anvendelse ifølge et hvilket som helst af kravene 12-13, hvor nævnte triptan skal administreres i en dosis på fra 0,001 til 10 mg/kg legemsvægt, såsom 0,001 til 5 mg/kg legemsvægt, såsom 0,01 til 1 mg/kg legemsvægt; og hvor 5-HT1A-agonis-ten skal administreres i en dosis på fra 0,01 til 10 mg/kg legemsvægt, såsom 0,01 til 5 mg/kg legemsvægt, såsom 0,1 til 1 mg/kg legemsvægt.
15. Farmaceutisk formulering ifølge et hvilket som helst af kravene 1 -11 eller farmaceutisk formulering til anvendelse ifølge et hvilket som helst af kravene 12-14, hvor formuleringen skal administreres i kombination med L-DOPA og/eller benzerazid, hvor L-DOPA og/eller benzerazid administreres sekventielt eller samtidigt.
DK13725557.6T 2012-04-18 2013-04-18 Oralt tilgængelig farmaceutisk formulering, som er egnet til forbedret behandling af bevægelseslidelser DK2838517T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201270196 2012-04-18
PCT/DK2012/050190 WO2012163365A1 (en) 2011-06-01 2012-06-01 Combinations of serotonin receptor agonists for treatment of movement disorders
DKPA201270755 2012-12-04
PCT/DK2013/050111 WO2013156035A1 (en) 2012-04-18 2013-04-18 Orally available pharmaceutical formulation suitable for improved management of movement disorders

Publications (1)

Publication Number Publication Date
DK2838517T3 true DK2838517T3 (da) 2018-01-15

Family

ID=49382938

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13725557.6T DK2838517T3 (da) 2012-04-18 2013-04-18 Oralt tilgængelig farmaceutisk formulering, som er egnet til forbedret behandling af bevægelseslidelser

Country Status (24)

Country Link
US (1) US10561618B2 (da)
EP (1) EP2838517B1 (da)
JP (1) JP6216768B2 (da)
KR (1) KR102104635B1 (da)
CN (1) CN104411301B (da)
AU (1) AU2013248685B2 (da)
BR (1) BR112014025907B1 (da)
CA (1) CA2870123C (da)
DK (1) DK2838517T3 (da)
ES (1) ES2654787T3 (da)
HK (1) HK1207285A1 (da)
HU (1) HUE037732T2 (da)
IL (1) IL235000B (da)
IN (1) IN2014DN09571A (da)
MX (1) MX361372B (da)
MY (1) MY169068A (da)
NO (1) NO2838517T3 (da)
NZ (1) NZ700474A (da)
PH (1) PH12014502331A1 (da)
PL (1) PL2838517T3 (da)
PT (1) PT2838517T (da)
RU (1) RU2670272C2 (da)
SG (1) SG11201406690SA (da)
WO (1) WO2013156035A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3160464B1 (en) * 2014-06-26 2018-07-18 Contera Pharma APS 6-hydroxybuspirone for use in the treatment of movement disorders
CN106456622B (zh) 2014-07-09 2020-05-19 皮埃尔法布雷医药公司 用贝非拉醇治疗运动障碍的方法
BR112017015487A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
US11135379B2 (en) 2019-02-15 2021-10-05 Bn Intellectual Properties, Inc. Method of delivering pharmaceutical products
US11559525B2 (en) 2019-04-26 2023-01-24 Sumitomo Pharma Co., Ltd. Therapeutic drug for dyskinesia
US10758535B1 (en) * 2019-04-26 2020-09-01 Sumitomo Dainippon Pharma Co., Ltd. Therapeutic drug for dyskinesia
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
MX2023002422A (es) 2020-08-31 2023-03-22 Sumitomo Pharma Co Ltd Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson.

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4182763A (en) 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4438119A (en) 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4687772A (en) 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4777173A (en) 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
US5185329A (en) 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
US6432956B1 (en) 1990-02-12 2002-08-13 William C. Dement Method for treatment of sleep apneas
IL114690A (en) 1990-06-07 1997-02-18 Wellcome Found Antimigraine oxazolidinone substituted indole derivatives
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
DE4122217C2 (de) * 1991-07-04 1997-02-13 Merz & Co Gmbh & Co Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
GB9209882D0 (en) 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
US5484788A (en) 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5637314A (en) 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US6150365A (en) 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
GB9928578D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
ATE374192T1 (de) 2000-11-29 2007-10-15 Lilly Co Eli 1-(2-m-methansulfonamidophenylethyl)-4-(m- trifluoromethylphenyl)piperazine und ihre akzeptablen pharmazeutischen salze und solvate und ihre verwendung zur behandlung von inkontinenz
WO2002053139A2 (en) 2001-01-05 2002-07-11 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
WO2003011255A1 (en) * 2001-07-04 2003-02-13 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
DK1427724T3 (da) * 2001-09-19 2006-08-21 Merck Patent Gmbh Hidtil ukendt anvendelse af substituerede aminomethylchromaner
JP2007508249A (ja) * 2003-10-10 2007-04-05 ライフサイクル ファーマ アクティーゼルスカブ フィブラートとスタチンを含む固体剤型
DE10353657A1 (de) 2003-11-17 2005-06-23 Merck Patent Gmbh Indolderivate
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
EP1711493A2 (en) 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
CA2572292A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
WO2006027681A1 (en) * 2004-09-07 2006-03-16 Pfizer Limited Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine
AU2005319367B2 (en) * 2004-12-20 2012-05-24 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
CA2594940A1 (en) * 2005-01-18 2006-07-27 Merck & Co., Inc. Cgrp receptor antagonists
CA2604052C (en) * 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
WO2007134077A2 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2654557A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and l-dopa
WO2008033155A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for prevention and treatment of rhinitis
WO2008047839A1 (fr) * 2006-10-19 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. Agoniste du récepteur de la 5-ht1a
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PREPARING RAPID DISAGGREGATION FORMULATION FOR ORAL ADMINISTRATION AND APPARATUS FOR PREPARING AND PACKAGING THEREFOR
EP2105130A1 (de) 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
EP2317996A1 (en) 2008-06-24 2011-05-11 Anders Björklund Eltoprazine for suppression of l-dopa induced dyskinesias
WO2010044736A1 (en) 2008-10-14 2010-04-22 Mcneil Ab Multi portion intra-oral dosage form and use thereof
GEP20146013B (en) 2009-01-23 2014-01-27 Aziende Chimiche Riunite Angelini Francesco A C R A F S P A It Controlled release pharmaceutical or food formulation and method of preparation thereof
EP2515654A4 (en) 2009-12-23 2013-04-24 Map Pharmaceuticals Inc NEW ERGOLINANALOGA
HUE031661T2 (en) 2010-10-15 2017-07-28 Contera Pharma Aps Combinations of serotonin receptor agonists for the treatment of movement disorders
EP2714040A1 (en) * 2011-06-01 2014-04-09 Concit Pharma ApS Combinations of serotonin receptor agonists for treatment of movement disorders

Also Published As

Publication number Publication date
MX361372B (es) 2018-12-05
KR102104635B1 (ko) 2020-04-27
RU2670272C2 (ru) 2018-10-22
IN2014DN09571A (da) 2015-07-17
MY169068A (en) 2019-02-12
RU2014145944A (ru) 2016-06-10
PL2838517T3 (pl) 2018-03-30
MX2014012408A (es) 2014-12-10
SG11201406690SA (en) 2014-11-27
NZ700474A (en) 2016-10-28
PH12014502331B1 (en) 2014-12-22
IL235000B (en) 2018-01-31
HK1207285A1 (en) 2016-01-29
CA2870123C (en) 2021-02-23
NO2838517T3 (da) 2018-03-17
HUE037732T2 (hu) 2018-09-28
ES2654787T3 (es) 2018-02-15
BR112014025907B1 (pt) 2023-02-14
PH12014502331A1 (en) 2014-12-22
AU2013248685B2 (en) 2017-07-27
CN104411301A (zh) 2015-03-11
US20150104506A1 (en) 2015-04-16
AU2013248685A1 (en) 2014-10-16
PT2838517T (pt) 2018-01-04
EP2838517A1 (en) 2015-02-25
EP2838517B1 (en) 2017-10-18
CA2870123A1 (en) 2013-10-24
US10561618B2 (en) 2020-02-18
CN104411301B (zh) 2018-02-06
JP2015514727A (ja) 2015-05-21
BR112014025907A2 (pt) 2017-06-20
JP6216768B2 (ja) 2017-10-18
KR20140146207A (ko) 2014-12-24
WO2013156035A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
DK2838517T3 (da) Oralt tilgængelig farmaceutisk formulering, som er egnet til forbedret behandling af bevægelseslidelser
US9259418B2 (en) Pharmaceutical compositions for treatment of Parkinson's disease
BR112020024107A2 (pt) combinação farmacêutica, composição, e preparação de combinação que compreende ativador de glucoquinase e inibidor de sglt-2 e métodos de preparação e uso dos mesmos
JP7227896B2 (ja) 朝の無動状態を治療するための拍動性薬物送達系
JP6634445B2 (ja) ブスピロン代謝産物の使用
EP3897641B1 (en) Treatment of movement disorders
EP2802319B1 (en) Fixed dose combination therapy of parkinson's disease